RxDoctor Payments Data

Walter Chiles, MD

Urology · Knoxville, TNNPI 1124019682

Payments from drug & device makers

$12,557in general payments, 2019–2025

Across 636 payments — averaging $19.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$1K
  • Sumitomo Pharma America, Inc.$959
  • Johnson & Johnson$809
  • Dendreon Pharmaceuticals LLC$578
  • Astellas Pharma US Inc$577
  • plus $7K from 44 others

What the payments were for

  • Food & beverage$12,45799%
  • Education$1001%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,557 in reported general payments places this provider in the 75th percentile of 276 urology providers in Tennessee.

See all urology providers in Tennessee

Medicare billing

Part B allowed, 2024
$441,342
Medicare patients
918
Services billed
9,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide32$523,359
XtandiEnzalutamide28$351,765
NubeqaDarolutamide24$311,296
OrgovyxRelugolix96$247,745
GemtesaVibegron180$146,530
MyrbetriqMirabegron123$92,344
Abiraterone Acetate14$59,986
Alfuzosin Hcl ErAlfuzosin Hcl517$11,477
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst131$8,164
Tamsulosin Hcl427$6,355
NitrofurantoinNitrofurantoin Macrocrystal54$3,052
Dutasteride90$2,806
Solifenacin Succinate45$2,666
Fesoterodine Fumarate ErFesoterodine Fumarate43$2,598
Potassium Citrate ErPotassium Citrate19$1,680

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$809$523,35932 claims
Astellas Pharma US IncXtandi, Myrbetriq$577$444,109151 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$959$394,275276 claims
BayerNubeqa$415$311,29624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 276 urology providers in Tennessee.

Other urology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →